Treatment with an oral antibiotic targeting Mycobacterium avium paratuberculosis (MAP) led to significant improvement in patients with Crohn’s disease, including clinical remissions, according to the results of a multinational randomized trial.
The drug, a fixed-dose combination of clarithromycin, rifabutin and clofazimine (RHB-104, RedHill Biopharma) is yet to be approved for Crohn’s. However, the findings strengthen the case that MAP infection may be the cause of at least some